In a report released today, Salim Syed from Mizuho Securities maintained a Hold rating on Amgen (AMGN – Research Report), with a price target of $200.00. The company’s shares closed last Monday at $254.99.
According to TipRanks.com, Syed has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -7.4% and a 43.9% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Coherus Biosciences.
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $261.08.
The company has a one-year high of $276.69 and a one-year low of $210.28. Currently, Amgen has an average volume of 2.62M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1980, California-based Amgen, Inc. is one of the world’s leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.